The FDA is to review Sanofi/Regeneron's Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema. Analysts predict peak annual ...

Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for review the resubmission of the supplemental Biologics License Application, or sBLA, for Dupixent to treat adults and ...

The priority review status is backed by positive results from two late-stage trials, evaluating the efficacy and safety of Dupixent in adults who were current or former smokers with uncontrolled COPD.

Dupixent's indications could be extended further if it is approved for the rare skin disease prurigo nodularis, currently under review at the FDA with a decision due in September. The drug is also ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Bristol Myers Squibb has continued its ruthless cost-cutting push, dropping plans to commercialize a rival to Dupixent despite meeting its phase 3 goals and pumping the brakes on a would-be ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

Furthermore, the successful launch of Dupixent for chronic obstructive pulmonary disease (COPD) has garnered significant coverage from top commercial and Medicare payers, indicating strong market ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...

Despite Eylea's market challenges, Dupixent's strong performance and future potential in COPD, along with a robust pipeline, position Regeneron for recovery in 2025. Regeneron's solid financials ...